Oncolytics Biotech Appoints Ex-Ambrx Chairman of $2B J&J Transaction, Elevates McAdory to COO
ONCY•Oncolytics Biotech appointed Steve Glover, former Ambrx chairman who oversaw its $2 billion sale to Johnson & Johnson, to its Board and promoted John McAdory to COO to oversee clinical and preclinical operations. Glover’s transaction expertise and McAdory’s operational leadership aim to accelerate pelareorep’s registration-enabling studies and strategic partnership initiatives.
1. Board Appointment of Steve Glover
Oncolytics Biotech has added Steve Glover to its Board of Directors. Glover previously served as Chairman of Ambrx Biopharma and led its acquisition by Johnson & Johnson in a transaction valued at approximately $2 billion, bringing deep expertise in corporate strategy, financings and strategic transactions.
2. Promotion of John McAdory to COO
John McAdory has been elevated to Chief Operating Officer, where he will manage the company’s clinical operations, development activities and preclinical research efforts. McAdory joined Oncolytics earlier this year after serving as Vice President of Clinical Operations at CG Oncology.
3. Implications for Pelareorep Development and Partnerships
These leadership changes are designed to boost execution of pelareorep’s registration-enabling studies in metastatic gastrointestinal cancers and expand the preclinical pipeline. The additions also strengthen Oncolytics’ ability to pursue and negotiate strategic partnerships to maximize the immunotherapy platform’s commercial potential.
